Clinical experience in treatment with the long-term insulin analogue glargin in a diabetes centre;Klinické zkušenosti s léčbou dlouhodobým inzulinovým analogem glargin v diabetologickém centru

Vnitrni Lekarstvi

Volumn 53, Issue 6, 2007, Pages 632-636

  Haladová, Iva ^a   Lacigova S ^a   Jankovec, Z ^a   Cechurova D ^a   Zourek M ^a   Krcma M ^a   Rusavy Z ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Diabetes mellitus; Glargin; Insulin; Lantus

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLARGINE; GLYCOSYLATED HEMOGLOBIN; INSULIN; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REDUCTION; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LONG TERM CARE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PATIENT MONITORING; SCORING SYSTEM; ADULT; BLOOD; FEMALE; MALE;

ADULT; DIABETES MELLITUS, TYPE 1; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE;

EID: 34347205205     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. The United Kingdom prospective diabetes study. The Lancet 1998; 352: 837-865.
2. Donabauer B, Schneider K, Schweitzer MA. Introduction of insulin glargin to basal-bolus therapy improves metabolic control in patients with type 1 diabetes in every day clinical practice. Diabetologia 2005; Suppl 1.
3. Peter R, Luzio SD, Dunseath G et al. Effects of exercise on the absorption of insulin glargine in patients with type 1 diabetes. Diabetes Care 2005; 28: 560-565.
4. Chase HP et al. Reduced hypoglycemic episodes and improved glycaemic control in children with type 1 diabetes using insulin glargine and neutral protamine Hagedom insulin. J Pediatr 2003; 143: 737-740.
5. Owens DR, Griffiths S. Insulin glargine (Lantus). Int J Clin Pract 2002; 56: 460-466.
6. Hamann A, Matthaei S, Rosak Ch et al. A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes. Diabetes Care 2003; 6: 1738-1744.
7. Witthaus E et al. Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with Type 1 diabetes. Diabet Med 2001; 18: 619-625.
8. Výbor České diabetologické společnosti ČLS JEP. Standardy péče o diabetes mellitus 1. typu. DMEV 2004; 1: 6-8.
9. Tan CY, Wilson DM, Buckingham B. Initiation of insulin glargine in children and adolescents with type 1 diabetes. Pediatric Diabetes 2004; 5: 80-86.
10. Hathout EH, Fujishige L, Geach J et al. Effect of therapy with insulin glargine (lantus) on glycemic control in toddlers, children, and adolescents with diabetes. Diabetes technology Therapeutics 2003; 5: 801-806.
11. Ashwell SG, Amiel SA, Biloust RW et al. Improved glycaemic control with insulin glargine plus insulin lispro: a multricentre, randomized, cross-over trial in people with Type 1 diabetes. Diabetes Med 2006; 23: 285-292.
12. Ratner R, Hirsch I, Neifing J et al. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care 2000; 23: 639-643.
13. Colino E, Lopez-Capape M, Gomlmayo L et al. Therapy with insulin glargine (Lantus) in toddlers, children and adolescents with type 1 diabetes. Diabetes Res Clin Pract 2005; 70: 1-7.
14. Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. Br Med J 2002; 324: 705.
15. Jankovec Z, Krcma M, Lacigova S et al. National Registry of Patients Treated with Continuous Subcutaneous Insulin Infusion (CSII) in the Czech Republic: Long-term results. Infusystem International 2005; 4: 21-24.
16. Jankovec Z, Čechurová D, Krčma M et al. Dlouhodobý efekt léčby inzulínovou pumpou (CSII) - výsledky Registru pacientů léčených CSII v České republice. XLII. Diabetologické dny, Luhačovice, 20.-22. 4. 2006. Diabetologie, Metabolismus, Endokrinologie, Výživa 2006; Suppl 2: 26.
17. The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995; 44: 968-983.
18. Bartoš V, Pelikánová T et al. Praktická diabetologie. 2. ed. Praha: Maxdorf 2000; 88.
19. Meyer C, Grossmann R, Mitrakou A et al. Effects of autonomic neuropathy on counterregulation and awareness of hypoglycemia in type 1 diabetic patients. Diabetes Care 1998; 21: 1960-1966.
20. Hirsch IB, Brownlee M. Should minimal blood glucose variability become the gold standard of glycemic control? Diabetes Complications 2005; 19: 178-181.
21. Garg SK, Paul JM, Karsten JI et al. Reduced severe hypoglycemia with insulin glargine in intensively treated adults with type 1 diabetes. Diabetes technology Therapeutics 2004; 6: 589-595.
22. Ashwell SG, Gebbie H, Home PD Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart. Diabet Med 2006; 23: 879-886.
23. Ashwell SG, Gebbie J, Home PD Optimal timing of injection of once-daily insulin glargine in people with Type 1 diabetes using insulin lispro at meal-times. Diabet Med 2006; 23: 46-52.